NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Cocrystal Pharma, Inc. COCP
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.78
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-111.4%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -0.78
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-111.4%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-76.2%
Each USD of equity lost 111 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 9.7M
total assets, end of FY2025
Total assetsUSD 9.7M
EquityUSD 6.3M
CashUSD 7.0M
Current ratio3.68×
Equity funds 65% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
·
·
·
0.0
0.0
·
·
·
·
·
·
·
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
·
·
·
Income tax $B
·
·
·
·
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.78
−1.72
−1.87
−4.77
−0.16
−0.17
−1.51
−1.75
−0.03
−3.30
−2.40
−0.01
−0.07
·
−0.11
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−111.4
−97.5
−54.5
−66.3
−21.8
−24.7
−104.0
−56.9
−0.6
−55.5
−57.5
·
·
·
·
·
Shares out B
0.01
0.01
0.01
0.01
0.01
0.07
0.04
0.03
0.02
0.02
0.69
0.00
0.00
0.06
0.06
0.04
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
46 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed